The estimated Net Worth of June Lee is at least 1.71 百万$ dollars as of 23 September 2019. June Lee owns over 13,051 units of MyoKardia stock worth over 934,051$ and over the last 8 years June sold MYOK stock worth over 776,665$.
June has made over 7 trades of the MyoKardia stock since 2018, according to the Form 4 filled with the SEC. Most recently June sold 13,051 units of MYOK stock worth 776,665$ on 23 September 2019.
The largest trade June's ever made was exercising 18,004 units of MyoKardia stock on 2 May 2018 worth over 215,148$. On average, June trades about 3,301 units every 32 days since 2017. As of 23 September 2019 June still owns at least 4,153 units of MyoKardia stock.
You can see the complete history of June Lee stock trades at the bottom of the page.
June's mailing address filed with the SEC is 333 Allerton Ave, South San Francisco, CA 94080, USA.
Over the last 9 years, insiders at MyoKardia have traded over 313,807,381$ worth of MyoKardia stock and bought 2,317,816 units worth 42,556,877$ . The most active insiders traders include Sanofi、Kevin P Starr、Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of 21,462,936$. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth 469,900$.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
MyoKardia executives and other stock owners filed with the SEC include: